ALLR (Allarity Therapeutics) COGS-to-Revenue : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics COGS-to-Revenue?

Allarity Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

Allarity Therapeutics's COGS to Revenue for the three months ended in Sep. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Allarity Therapeutics's Gross Margin % for the three months ended in Sep. 2024 was N/A%.

Allarity Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Allarity Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics COGS-to-Revenue Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Allarity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial													-	-	-	-	-

Allarity Therapeutics COGS-to-Revenue Calculation

Allarity Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Allarity Therapeutics's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Allarity Therapeutics (NAS:ALLR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Allarity Therapeutics's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Allarity Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 School Street, 2nd Floor, Boston, MA, USA, 02108

Website

https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Executives

Laura Benjamin	director	168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano	director	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown	officer: Chief Financial Officer	C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi	director, officer: Chief Executive Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen	officer: Chief Scientific Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen	officer: Chief Financial Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore	director	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen	officer: SVP, Information Technology	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem	officer: SVP, Chief Business Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh	officer: Chief Medical Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps	10 percent owner	VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass	10 percent owner	JERNBAEK ALLE 5, HELSINGE G7 DK-3200